TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Supplemental O2 flow volume in L/min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fold Change in IL-5 Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Independence scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rise of serum creatinine in mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: decreased spontaneous brain activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Numbers of Participants With Non-serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Numbers of Participants With Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with causative pathogens and susceptibility profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Blood myeloid dendritic cell level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in pain qualities (intensity, location, interference)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wheal and flare surface areas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stiffness of lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Assessment of 5-ALA doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in radiotherapy recommendation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number and Percentage of Participants With Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number and Percentage of Participants With Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number and Percentage of Participants With Deaths
Endpoint domain: Mortality/survival
Primary endpoint: paucity of major complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Physician's Global Assessment of disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early liver rejection
Endpoint domain: Adverse events/effects
Primary endpoint: Change in RHI (Reactive Hyperemia Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Efficacy of Bisacodyl and Lactulose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Inflammation characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maturation effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in [D10]phenanthrene tetraol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and Percentage of Subjects With ACR20 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and Percentage of Subjects With ACR50 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and Percentage of Subjects With ACR70 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive development and performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: area under the curve (AUC 0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Referral rate for preventive dental services
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Parasite density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Medically-attended injury
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in ocular surface integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Useful Field of View
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Yale Brown obsessive compulsive scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Blood pressure measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adverse Pregnancy Outcomes (APC)
Endpoint domain: Adverse events/effects
Primary endpoint: Liver MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency, severity and characteristics of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Hemodynamic measures during childbirth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: EBI2 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in serum levels of triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in serum levels of adiponectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in serum levels of tumor necrosis factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adverse effects/toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Change in clinician behavior
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Repeatability of diagnostic methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reproducibility of diagnostic methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistent Headache Pain Free at 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of teeth with treatment-related success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pregnancy adaptation scale
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: AUC of lobeglitazone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax of lobeglitazone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC of S-warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax of S-warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC of R-warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax of R-warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: sustained return of spontaneous circulation (ROSC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virological suppression (plasma HIV-RNA < 50 copies/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital for Special Surgery knee score (HSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inguinal recurrence rates
Endpoint domain: Mortality/survival
Primary endpoint: Post-operative Urinary Incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Safety of PBI-directed external-beam radiation therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants who initiate PrEP
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of participants who attend follow-up visits and have documented PrEP prescription refills
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of participants who adhere to their PrEP regimen
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area Under the Concentration-Time Curve (AUC 0-tz) for Empagliflozin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve (AUC 0-tz) for Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Measured Concentration (Cmax) for Empagliflozin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Measured Concentration (Cmax) for Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropsychological assessment 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neuropsychological assessment 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Right ventricle (RV) to Left ventricle (LV) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pulmonary pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical labs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine safety markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Negative Appendicectomy Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Increased Open Appendicectomy Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Surgical site infection in patients on antibiotics
Endpoint domain: Adverse events/effects
Primary endpoint: New WHO Stage 3 or 4 Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Virologic Failure, FDA Snapshot (HIV-2 Plasma Viral Load >50 and >400 Copies/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weekly Standardized Dialysis Adequacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Pre-Specified Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Phosphorous level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: post-treatment prostate biopsy outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improved diagnostic accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic parameters (AUC(0-inf), Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Glaucoma Symptom Scale questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Brief Pain Inventory (BPI)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in specific 32 gene products
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour ambulatory diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Contamination with HIV-1 or -2
Endpoint domain: Adverse events/effects
Primary endpoint: successful behavior change
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: uNTx/uCr
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: target vessel occlusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Feasibility of identification of sentinel nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Differential micro ribonucleic acid expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean per-procedural pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in gene-arrays
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EPC (Endothelial Progenitor Cells)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: biomarkers panels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of TH Clients Who Received HIV Testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Clarity of mucosal lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major adverse cardiac event
Endpoint domain: Mortality/survival
Primary endpoint: Train of four ratio >0.9
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neuromuscular outcomes
Primary endpoint: Overall successful Cannulation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Psychological impacts
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sleepiness during the night shifts
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Interobserver variability of Clinical Target Volume boost
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of delineated Clinical Target Volume boost
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Revised Fibromyalgia Impact Questionnaire (FIQR)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Client Service Receipt Inventory (CSRI)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: pro- and anti-inflammatory cytokines & hs-CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Functional brain response pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Locoregional failure-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Distant failure-free survival
Endpoint domain: Mortality/survival
Primary endpoint: skin ageing scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: CAR T cell persistence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hs-Troponin-I levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Islet yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Critical Shoulder Angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acromial Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance in sleep apnea management
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: CGRP levels during migraine phases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline Electrical Activity of the Anterior Part of the Temporal and Masseter Muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change From Baseline in Muscle Pain Scores on the Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the CRS-R total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor Promoting Effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline on Fasting Insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of automatic or implicit associations of Alcohol with positive affect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Arterial Spin Labeling (ASL) signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Damage of the air-blood membrane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of receptors in mucosal biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Provider Ranking
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient Health Questionnaire 9-item (PHQ-9)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Generalized Anxiety Disorder (GAD-7)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Myocardial protection against ischemic injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nasopharyngeal pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Timed 10-meter walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve (AUC[0-tlast]) of Baseline-Adjusted Glucagon
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Concentration (Tmax) of Baseline Adjusted Glucagon
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline-Adjusted Glucose Maximum Concentration (BGmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nipple crack change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Activation/deactivation in fMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Fluctuations in gastrointestinal inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Disability on Instrumental Activities of Daily Living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Visual Analogue Scale (VAS) 0 to 10
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: number of sutures used
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: number of patients with wound complications (infection, hematoma, disruption)
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended dose of ADH-1
Endpoint domain: Adverse events/effects
Primary endpoint: Time to Loss of Consciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Awakening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Quadriceps Muscle Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of OSA defined by AHI of at least 15/h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants With Very Good Partial Response or Better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC Zero to Infinity (AUC0-∞) for Serum Deferiprone and Deferiprone 3-O-glucuronide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Current active HBV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: HBV infection carrier status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: HCV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: HDV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: HIV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: AUC 0-240 min post-prandial serum glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Postoperative Pancreatic Fistula
Endpoint domain: Adverse events/effects
Primary endpoint: Detection rate of ACTH producing microadenoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change From Baseline in Tissue Glycogen Content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pharmacokinetic parameters (Ctrough, Cmax, Tmax, AUC0-8h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conversion from Unresectable to Resectable Liver Metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of subjects with injection site reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Response Using Clinical Global Impressions-Improvement Scale (CGI-I)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participant compliance with the intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: VO2max Aerobic Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximal voluntary contraction (MVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic Critical Illness
Endpoint domain: Mortality/survival
Primary endpoint: Early Death
Endpoint domain: Mortality/survival
Primary endpoint: Area of Hemangioma lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Color of lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shape of lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing Hypoxemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Peak Venous Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Impaired performance following concussion
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Visual reading ability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Visual mobility
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning